Memorandum

TO: Directors, Health Service Regions
    Immunization Program Managers, Health Service Regions
    Directors, Local Health Departments
    Immunization Program Managers, Local Health Departments

FROM: Karen Hess, Manager
       Vaccine Services Group

THRU: Jack Sims, Manager
       Immunization Branch

DATE: August 16, 2010

SUBJECT: Texas Vaccines for Children Program: 2010-2011 Influenza Vaccine

Texas Vaccines for Children (TVFC) seasonal influenza vaccine orders were placed earlier this year, and should begin shipping to providers as vaccines become available from the Centers for Disease Control and Prevention (CDC). Please refer to the attached one page reference sheet for a list of vaccines, dosages, and age groups. TVFC influenza vaccine is reserved for children 6 months to 18 years of age as indicated below:

TVFC Children Eligible for Trivalent inactivated Influenza Vaccine (TIV)
   o All children aged 6 months through 18 years.

TVFC Children Eligible for Live, Attenuated Influenza Vaccine (LAIV)
   o All healthy children and adolescents (those who do not have an underlying medical condition that predisposes them to flu complications) aged 2 years through 18 years.

The 2010-11 trivalent vaccines will contain A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens. The influenza A (H1N1) vaccine virus is derived from a 2009 pandemic influenza A (H1N1) virus. Providers may begin immunizing as vaccine becomes available and should continue vaccination efforts throughout the season. The duration of influenza seasons vary, and influenza may not begin to appear in certain communities until as late as February or March. For additional information on influenza vaccine recommendations, visit the following website:
http://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0729a1.htm?s_cid=rr59e0729a1_e

By federal law, an appropriate Vaccine Information Statement (VIS) must be given to all patients, or their parent or legal representative when receiving an influenza vaccine. Influenza VISs for 2010-11 are expected to become available in early September. VISs will not be
included with influenza vaccine shipments and must be ordered by providers. There are two VISs, one for TIV (Stock # C-93 or Spanish C-93A) and the LAIV (Stock # C-87 or Spanish C-87A) including addenda. To order influenza VISs directly from the Immunization Branch, please visit https://secure.immunizetexasorderform.com/default.asp. If you do not have access to the web, or if you have questions or concerns regarding ordering immunization literature or forms call 1-800-252-9152. VISs without the Texas Addendum are available now online at the following CDC websites:
TIV: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-flu.pdf,

If you have questions regarding the seasonal influenza vaccine, please call your local health department, health service region, or TVFC Consultant.

Attachments:
TVFC 2010-11 Influenza Vaccine Dosages and Information
<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Trade name</th>
<th>Manufacturer</th>
<th>Presentation</th>
<th>Mercury content (mcg Hg/0.5 mL dose)</th>
<th>Age group</th>
<th>No. of doses</th>
<th>Route</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIV†</td>
<td>Fluzone</td>
<td>sanofi pasteur</td>
<td>0.25 mL prefilled syringe</td>
<td>0.0</td>
<td>6–35 mos</td>
<td>1 or 2§</td>
<td>Intramuscular¶</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.5 mL prefilled syringe</td>
<td>0.0</td>
<td>≥36 mos</td>
<td>1 or 2§</td>
<td>Intramuscular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.5 mL vial</td>
<td>0.0</td>
<td>≥36 mos</td>
<td>1 or 2§</td>
<td>Intramuscular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.0 mL multidose vial</td>
<td>25.0</td>
<td>≥6 mos</td>
<td>1 or 2§</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>TIV</td>
<td>Fluvin</td>
<td>Novartis Vaccine</td>
<td>5.0 mL multidose vial</td>
<td>24.5</td>
<td>≥4 yrs</td>
<td>1 or 2§</td>
<td>Intramuscular</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.5 mL prefilled syringe</td>
<td>&lt;1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIV</td>
<td>Fluarix</td>
<td>Glaxo SmithKline</td>
<td>0.5 mL prefilled syringe</td>
<td>0.0</td>
<td>≥3 yrs</td>
<td>1</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>TIV</td>
<td>FluLaval</td>
<td>Glaxo SmithKline</td>
<td>5.0 mL multidose vial</td>
<td>25.0</td>
<td>≥18 yrs</td>
<td>1</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>TIV</td>
<td>Afluria#</td>
<td>CSL Biotherapies</td>
<td>0.5 mL prefilled syringe</td>
<td>0.0</td>
<td>≥9 yrs#</td>
<td>1</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>LAIV††</td>
<td>FluMist§§</td>
<td>MedImmune</td>
<td>0.2 mL sprayer, divided dose</td>
<td>0.0</td>
<td>2–49 yrs</td>
<td>1 or 2§</td>
<td>Intranasal</td>
</tr>
</tbody>
</table>

* Immunization providers should check Food and Drug Administration--approved prescribing information for 2010–11 influenza vaccines for the most updated information.

† Trivalent inactivated vaccine.

§ Children aged 6 months–8 years who have never received a seasonal TIV before or who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses, spaced ≥4 weeks apart. Those children aged 6 months–8 years who were vaccinated for the first time in the 2009–10 seasons with the seasonal 2009–10 seasonal vaccines but who received only 1 dose should receive 2 doses of the 2010–11 influenza vaccine formula, spaced ≥4 weeks apart.

¶ For adults and older children the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolateral aspect of the thigh.

# Afluria should not be used in children aged 6 months through 8 years. If no other age-appropriate, licensed seasonal influenza vaccine is available for a child aged 5 years through 8 years old who has a medical condition that increases their risk for influenza complications, Afluria may be given, and providers should discuss the benefits and risks of influenza vaccination with the parents or caregivers before administering Afluria. See website for more details [http://www.cdc.gov/flu/professionals/vaccine/qv_esfluvac.htm#arecsfluv](http://www.cdc.gov/flu/professionals/vaccine/qv_esfluvac.htm#arecsfluv).

†† Live attenuated influenza vaccine.

§§ FluMist is shipped refrigerated and stored in the refrigerator at 36°F–46°F (2°C–8°C) after arrival in the vaccination clinic. The dose is 0.2 mL divided equally between each nostril. Health-care providers should consult the medical record, when available, to identify children aged 2–4 years with asthma or recurrent wheezing that might indicate asthma. In addition, to identify children who might be at greater risk for asthma and possibly at increased risk for wheezing after receiving LAIV, parents or caregivers of children aged 2–4 years should be asked: "In the past 12 months, has a health-care provider ever told you that your child had wheezing or asthma?" Children whose parents or caregivers answer "yes" to this question and who have asthma or who had a wheezing episode noted in the medical record within the past 12 months should not receive FluMist.